Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Ron J Keizer"'
Publikováno v:
PLoS Computational Biology, Vol 16, Iss 8, p e1008107 (2020)
Standard treatment for active tuberculosis (TB) requires drug treatment with at least four drugs over six months. Shorter-duration therapy would mean less need for strict adherence, and reduced risk of bacterial resistance. A system pharmacology mode
Externí odkaz:
https://doaj.org/article/da402b95bb604db8899366d79c651b02
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
Autor:
Imke H. Bartelink, Brendan Prideaux, Gregor Krings, Lisa Wilmes, Pei Rong Evelyn Lee, Pan Bo, Byron Hann, Jean-Philippe Coppé, Diane Heditsian, Lamorna Swigart-Brown, Ella F. Jones, Sergey Magnitsky, Ron J Keizer, Niels de Vries, Hilde Rosing, Nela Pawlowska, Scott Thomas, Mallika Dhawan, Rahul Aggarwal, Pamela N. Munster, Laura J. Esserman, Weiming Ruan, Alan H. B. Wu, Douglas Yee, Véronique Dartois, Radojka M. Savic, Denise M. Wolf, Laura van ’t Veer
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-17 (2017)
Abstract Background Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some
Externí odkaz:
https://doaj.org/article/36493b79564d44c2b1b8ca3d6cd7f195
Autor:
Jordan T. Brooks, Ron J. Keizer, Janel R. Long-Boyle, Sandhya Kharbanda, Christopher C. Dvorak, Brian D. Friend
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: With a notably narrow therapeutic window and wide intra- and interindividual pharmacokinetic (PK) variability, initial weight-based dosing along with routine therapeutic drug monitoring of tacrolimus are employed to optimize its clinical
Externí odkaz:
https://doaj.org/article/4cec0f044ca04910b9a50ec39f3f3173
Autor:
Praveen Shukla, Srijib Goswami, Ron J. Keizer, Beth Apsel Winger, Sandhya Kharbanda, Christopher C. Dvorak, Janel Long-Boyle
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
IntroductionPopulation pharmacokinetic (PK) studies demonstrate model-based dosing for busulfan that incorporates body size and age improve clinical target attainment as compared to weight-based regimens. Recently, for clinical dosing of busulfan and
Externí odkaz:
https://doaj.org/article/ca27ae567b09479ab6e924eb35908b01
Autor:
Adam Frymoyer, Hayden T. Schwenk, Yvonne Zorn, Laura Bio, Jeffrey D. Moss, Bhavin Chasmawala, Joshua Faulkenberry, Srijib Goswami, Ron J. Keizer, Shabnam Ghaskari
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
BackgroundModel-informed precision dosing (MIPD) can serve as a powerful tool during therapeutic drug monitoring (TDM) to help individualize dosing in populations with large pharmacokinetic variation. Yet, adoption of MIPD in the clinical setting has
Externí odkaz:
https://doaj.org/article/ef886d4cf4034249bfe305e0b6882dda
Publikováno v:
Clinical Pharmacokinetics. 62:67-76
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4940197145f83112243048de2ad5b176
https://doi.org/10.1007/s40262-022-01185-4
https://doi.org/10.1007/s40262-022-01185-4
Publikováno v:
Pharmaceutics; Volume 14; Issue 10; Pages: 2089
Model-informed precision dosing (MIPD) can aid dose decision-making for drugs such as gentamicin that have high inter-individual variability, a narrow therapeutic window, and a high risk of exposure-related adverse events. However, MIPD in neonates i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88faef6544891ea3853e5e9cf712c1b9
Publikováno v:
Clinical pharmacology and therapeutics.
Precision dosing aims to tailor doses to individual patients with the goal of improving treatment efficacy and avoiding toxicity. Clinical decision support software (CDSS) plays a crucial role in mediating this process, translating knowledge derived
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b0e3a195041bc690ea68a5bb2996fef
https://pubmed.ncbi.nlm.nih.gov/36408716
https://pubmed.ncbi.nlm.nih.gov/36408716
Autor:
Ron J. Keizer, Jonathan D. Faldasz, Srijib Goswami, Sarah Scarpace Lucas, Dominic M. H. Tong, Jasmine H. Hughes
Publikováno v:
Clinical Pharmacology and Therapeutics
Model‐informed precision dosing (MIPD) leverages pharmacokinetic (PK) models to tailor dosing to an individual patient’s needs, improving attainment of therapeutic drug exposure targets and thus potentially improving drug efficacy or reducing adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56ca5663a75db8ea2d6245d7fdb9840c
https://doi.org/10.1002/cpt.2088
https://doi.org/10.1002/cpt.2088
Autor:
Marith I. Francke, Dennis A. Hesselink, Louise M. Andrews, Teun van Gelder, Ron J. Keizer, Brenda C. M. de Winter
Publikováno v:
Therapeutic Drug Monitoring, 44(5), 606-614. LIPPINCOTT WILLIAMS & WILKINS
Therapeutic Drug Monitoring, 44(5), 606-614. Lippincott Williams & Wilkins
Therapeutic Drug Monitoring, 44(5), 606-614. Lippincott Williams & Wilkins
BACKGROUND: Initial algorithm-based dosing appears to be effective in predicting tacrolimus dose requirement. However, achieving and maintaining the target concentrations is challenging. Model-based follow-up dosing, which considers patient character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4f0c63a7e8190655b33b8e972267ee
https://pubmed.ncbi.nlm.nih.gov/35344525
https://pubmed.ncbi.nlm.nih.gov/35344525